<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl3">
 <label>Table 3</label>
 <caption>
  <p>Facts and open issues about COVID-19</p>
 </caption>
 <alt-text id="alttext0020">Table 3</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Facts about COVID-19</th>
    <th>Questions needing further assessment</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>
     <list list-type="simple" id="ulist0010">
      <list-item id="u0010">
       <label>•</label>
       <p id="p0130">SARS-CoV-2 is more phylogenetically related to SARS-CoV than to MERS-CoV</p>
      </list-item>
      <list-item id="u0015">
       <label>•</label>
       <p id="p0135">Only minor differences have been found between the genome sequences of SARS-CoV-2 and SARS-CoV</p>
      </list-item>
      <list-item id="u0020">
       <label>•</label>
       <p id="p0140">SARS-CoV-2 affinity for angiotensin-converting enzyme 2 (ACE2) receptor is higher than that of SARS-CoV</p>
      </list-item>
      <list-item id="u0025">
       <label>•</label>
       <p id="p0145">COVID-19 fatality rate is lower than that found in SARS and MERS</p>
      </list-item>
      <list-item id="u0030">
       <label>•</label>
       <p id="p0150">SARS-CoV-2 RNA has been detected in the stools of infected patients, similarly to SARS-CoV and MERS-CoV</p>
      </list-item>
      <list-item id="u0035">
       <label>•</label>
       <p id="p0155">1.2% of COVID-19 cases are asymptomatic</p>
      </list-item>
      <list-item id="u0040">
       <label>•</label>
       <p id="p0160">COVID-19 is not very different from SARS and MERS regarding demographic characteristics, laboratory and radiological findings</p>
      </list-item>
      <list-item id="u0045">
       <label>•</label>
       <p id="p0165">Clinical complications in COVID-19 are as frequent as in SARS, but less frequent than in MERS</p>
      </list-item>
      <list-item id="u0050">
       <label>•</label>
       <p id="p0170">Viral loads in COVID-19 patients are higher at the time of symptom onset and progressively decrease during the clinical course of the disease</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="ulist0015">
      <list-item id="u0055">
       <label>•</label>
       <p id="p0175">What is the role of amino acid substitutions on the SARS-CoV-2 receptor binding domain in terms of pathogenesis?</p>
      </list-item>
      <list-item id="u0060">
       <label>•</label>
       <p id="p0180">Does the higher affinity of SARS-CoV-2 than SARS-CoV for angiotensin-converting enzyme 2 (ACE2) receptor have an implication in respiratory complications?</p>
      </list-item>
      <list-item id="u0065">
       <label>•</label>
       <p id="p0185">Is the faecal–oral route of transmission possible for COVID-19?</p>
      </list-item>
      <list-item id="u0070">
       <label>•</label>
       <p id="p0190">What is the role of asymptomatic COVID-19 cases in the epidemiology of the disease?</p>
      </list-item>
      <list-item id="u0075">
       <label>•</label>
       <p id="p0195">What is the actual COVID-19 basic reproductive number (R
        <sub>0</sub>)?
       </p>
      </list-item>
      <list-item id="u0080">
       <label>•</label>
       <p id="p0200">Are differences in viral kinetics in the respiratory tract responsible for the different spreading potential of COVID-19, SARS and MERS?</p>
      </list-item>
     </list>
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
